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The aim of this study was to evaluate the benefits and risks of omega-3 fatty acid supplementation in patients
with chronic kidney disease. A systematic search of articles in PubMed, Embase, the Cochrane Library, and
reference lists was performed to find relevant literature. All eligible studies assessed proteinuria, the serum
creatinine clearance rate, the estimated glomerular filtration rate, or the occurrence of end-stage renal disease.
Standard mean differences with 95% confidence intervals for continuous data were used to estimate the effects
of omega-3 fatty acid supplementation on renal function, as reflected by the serum creatinine clearance rate,
proteinuria, the estimated glomerular filtration rate, and relative risk. Additionally, a random-effects model
was used to estimate the effect of omega-3 fatty acid supplementation on the risk of end-stage renal disease.
Nine randomized controlled trials evaluating 444 patients with chronic kidney disease were included in the
study. The follow-up duration ranged from 2 to 76.8 months. Compared with no or low-dose omega-3 fatty acid
supplementation, any or high-dose omega-3 fatty acid supplementation, respectively, was associated with a
lower risk of proteinuria (SMD: -0.31; 95% CI: -0.53 to -0.10; p=0.004) but had little or no effect on the serum
creatinine clearance rate (SMD: 0.22; 95% CI: -0.40 to 0.84; p=0.482) or the estimated glomerular filtration rate
(SMD: 0.14; 95% CI: -0.13 to 0.42; p=0.296). However, this supplementation was associated with a reduced risk of
end-stage renal disease (RR: 0.49; 95% CI: 0.24 to 0.99; p=0.047). In sum, omega-3 fatty acid supplementation is
associated with a significantly reduced risk of end-stage renal disease and delays the progression of this disease.
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’ INTRODUCTION
People with chronic kidney disease are at a particularly
high risk of developing end-stage renal disease (ESRD) and
all-cause mortality (1,2). The addition of omega-3 fatty acid
supplements to the diet has been well documented to affect
the risk factors for cardiovascular diseases (3,4). Over the
past few decades, many studies have shown that omega-3
fatty acids are also clearly effective at reducing proteinuria
in patients with chronic glomerular disease (5,6). In addi-
tion, the effect of omega-3 fatty acids on proteinuria is
dose dependent and associated with a dose-dependent effect
on plasma phospholipid eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) levels. These facts are worth
exploring further (7). However, the effects of omega-3 fatty
acids on renal function and subsequent ESRD events have
not been confirmed.
Several studies have indicated that short- or long-term
intervention with omega-3 fatty acids might reduce the
risk of ESRD and proteinuria and increase the creatinine
clearance rate (CCR) (8,9). In contrast, several other studies
have shown no significant association of omega-3 fatty acids
with a reduced risk of renal failure (10-16). These varying
results prompted the present study, which examined the
available relevant randomized controlled trials (RCTs) to
determine the effect of omega-3 fatty acids on the risk of
proteinuria and on the CCR, the estimated glomerular
filtration rate (eGFR), and the occurrence of ESRD in patients
with chronic kidney disease.
’ MATERIALS AND METHODS
Data sources, search strategy, and selection criteria
This review was conducted and reported according to the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis Statement issued in 2009 (Checklist S1) (17).
Any RCTs that examined the effect of omega-3 fatty acid
supplementation in patients with chronic kidney diseaseDOI: 10.6061/clinics/2017(01)10
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were eligible for inclusion in the study, and no restrictions
were placed on language or publication status (i.e., pub-
lished, in press, or in progress). The PubMed, Embase, and
Cochrane Library electronic databases were searched for
articles published through October 2014, with search terms
including ‘‘omega-3 fatty acids’’ OR ‘‘fish oil’’ OR ‘‘polyun-
saturated fatty acids’’ OR ‘‘eicosapentaenoic acid’’ OR ‘‘EPA’’
OR ‘‘docosahexaenoic acids’’ OR ‘‘DHA’’ AND (‘‘nephro-
pathy’’ OR ‘‘kidney disease’’) AND ‘‘human’’ AND ‘‘clinical
trial’’. Manual searches of the reference lists from all relevant
original and review articles were also conducted to identify
additional eligible studies. The medical subject headings,
methods, patient populations, designs, interventions, and
outcome variables of these studies were used to identify the
relevant articles.
The literature search was independently undertaken by
2 authors using a standardized approach. Any inconsistencies
between these 2 authors were reviewed by the primary author
to reach a consensus. A study was eligible for inclusion if the
following criteria were met: (1) design as an RCT or quasi-
RCT; (2) reporting of at least 1 outcome related to proteinuria,
the CCR, the eGFR, or the occurrence of ESRD; and (3) com-
parison of the effects of adding any dose or a high dose of
omega-3 fatty acids with no or low-dose omega-3 fatty acid
supplementation, respectively.
Data collection and quality assessment
All data from eligible trials were independently abstracted,
in duplicate, by 2 independent investigators using a standard
protocol and were reviewed by a third investigator. Any
discrepancies were resolved by group discussion, and the
primary author made the final decision. The recorded
variables were as follows: first author’s name, publication
year, study design, type of blinding, number of subjects,
mean age, percentage male, current disease status, interven-
tion regimens, duration of the follow-up period, and out-
comes of each group. Study quality was assessed using the
Jadad score (18), which is based on the following 5 subscales:
randomization (1 or 0), concealment of the treatment alloca-
tion (1 or 0), blinding (1 or 0), completeness of the follow-up
(1 or 0), and the use of intention-to-treat analysis (1 or 0). A
‘‘score system’’ (ranging from 1 to 5) was also developed for
quality assessment. A study given a score of 4 or higher was
considered to be one of high quality.
Statistical analyses
The results of each RCT were recorded as dichotomous
frequency or continuous data. Individual study relative risks
(RRs) and 95% confidence intervals (CIs) or standard mean
differences (SMDs) were also abstracted from each trial
before data pooling. Both fixed-effects and random-effects
models were used to assess the pooled RR or SMD for any
dose or a high dose of omega-3 fatty acids compared with no
or low-dose omega-3 fatty acid supplementation, respec-
tively. The results from the random-effects model presen-
ted here assume that the true underlying effect varied among
the included trials (19,20). Heterogeneity of the treatment
effects among studies was investigated using the Q statistic,
and po0.10 was considered to indicate significant hetero-
geneity (21,22). Subgroup analyses were also conducted for
proteinuria, the CCR, and the eGFR on the basis of country,
mean age, percentage male, current disease status, duration
Figure 1 - Selection of studies for the meta-analysis.
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of the follow-up period, and study quality, whereas these
analyses were not performed for ESRD outcome because of
the small number of trials with available data. Additionally,
a sensitivity analysis was performed by removing each trial
from the meta-analysis (23). Here, p values for heterogeneity
between subgroups were assessed using the Chi-square test
and meta-regression (24). Several methods were also used to
check for potential publication bias: visual inspection of
funnel plots for proteinuria, the CCR, and the eGFR were
conducted, and the Egger (25) and Begg (26) tests were used
to statistically and quantitatively assess publication bias for
these three parameters. All reported p values are two sided,
and po0.05 was considered statistically significant for all
included studies. The statistical analyses were performed
using Stata version 10.0 (StataCorp LP, College Station, TX,
USA). Because of the lack of relevant data, funnel plots and
the Egger (25) and Begg (26) tests were not used to analyze
ESRD.
’ RESULTS
The study selection process is shown in Figure 1. We
identified 171 articles in our initial electronic search, 137 of
which were excluded after duplicates and irrelevant studies
were removed. Therefore, 34 potentially eligible studies were
queried. After detailed evaluation, 9 RCTs (8-16) were
selected for the final meta-analysis. Omega-3 fatty acid sup-
plementation for the treatment of patients with chronic
kidney disease compared with no omega-3 fatty acid supple-
mentation was studied in 8 trials (8-11,13-16); the remain-
ing trial (12) studied high-dose compared with low-dose
omega-3 fatty acid supplementation. A manual search of the
reference lists of these studies did not yield any new eligible
studies. The general characteristics of the included studies
are presented in Table 1.
Of the 9 included trials, comprising 444 patients, with 23 to
106 per trial, the follow-up period for the participants was
2.0 to 76.8 months. Two studies (8,12) were conducted in the
United States; 2 (10,15), in Japan; 3 (9,11,14), in Europe; and
2 (13,16), in Australia. Seven studies (8-14) investigated the
effect of omega-3 fatty acids on IgA nephropathy, and 2 trials
(15,16) evaluated the effect on patients with chronic kidney
disease. Study quality was assessed using the Jadad score
(18) (Table 1), and a study with a scoreX4 was considered to
be of high quality. Three studies (12,13,16) had a score of 4,
while 5 studies (8,9,11,14,15) had a score of 3, and 1 study
(10) had a score of 2.
Data for the effect of omega-3 fatty acid supplementation
on proteinuria were available from 7 trials (8,9,11,13-16).
Overall, omega-3 fatty acid supplementation was associated
with a lower risk of proteinuria (SMD: -0.31; 95% CI: -0.53 to
-0.10; p=0.004), and there was no observed heterogeneity
across the trials (p=0.512, Figure 2).
Data for the effect of omega-3 fatty acid supplementation
on the CCR were available from 6 trials (10,11,13-16).
Overall, omega-3 fatty acid supplementation did not have
a statistically significant effect on the CCR (SMD: 0.22; 95%
CI: -0.40 to 0.84; p=0.482). Substantial heterogeneity was
detected across the included trials (po0.001, Figure 3);
however, based on sequential exclusion of each trial from
all pooled analyses, the conclusion was not affected by the
exclusion of any specific trial.
Data for the effect of omega-3 fatty acid supplementation
on the eGFR were available from 6 trials (8,9,11,13,14,16).
Overall, the effect of omega-3 fatty acid supplementation
on the eGFR was not statistically significant (SMD: 0.14; 95%
CI: -0.13 to 0.42; p=0.296; with nonsignificant heterogeneity;
Figure 4).
The effect of omega-3 fatty acid supplementation on
the occurrence of ESRD was examined using data from
207 patients and 44 ESRD events (8,11,12). Omega-3 fatty
acid supplementation significantly reduced the risk of ESRD
(RR: 0.49; 95% CI: 0.24 to 0.99; p=0.047; with moderate het-
erogeneity; Figure 5).
Subgroup analyses were conducted for proteinuria, the
CCR, and the eGFR to minimize heterogeneity among the
included trials and to evaluate the effect of omega-3 fatty
acid supplementation on specific populations (Table 2).
Omega-3 fatty acid supplementation was found to be
associated with a reduction in proteinuria if the study was
conducted in the United States or Australia, if the mean age
was o40 years, if the percentage male was 460%, if the
Table 1 - Design and characteristics of the trials included in the meta-analysis.
Source Publication
year
Country No. of
patients
Mean
age, y
Percentage
male (%)
Disease
status
Treatment Control Follow-up
(months)
Jadad
score
Uchiyama-Tanaka
and Mori (10)
2010 Japan 23 30.6 39.1 IgA
nephropathy
EPA 1.8 g/d plus angiotensin-
converting enzyme inhibitor
(ACEI)/angiotensin-receptor
blocker (ARB)
ACEi/ARB 12 2
Alexopoulos
et al. (11)
2004 Greece 28 40.0 78.6 IgA
nephropathy
EPA and PHA
5 g/d
Supportive
treatment
48 3
Donadio et al. (12) 2001 USA 73 45.5 52.1 IgA
nephropathy
2.94 g/d EPA and DHA 1.47 g/d
EPA and
DHA
24 4
Donadio et al. (8) 1999 USA 106 37.0 73.6 IgA
nephropathy
EPA 1.9 g/d plus DHA 1.4 g/d Placebo 76.8 4
Ferraro et al. (9) 2009 Italy 30 40.5 60.0 IgA
nephropathy
RASB and PUFAs 3.0 g/d
RASB
RASB 6 3
Bennett et al. (13) 1989 Australia 37 39.0 57.0 IgA
nephropathy
EPA 10 g/d Untreated 24 4
Pettersson
et al. (14)
1994 Sweden 32 41.0 78.0 IgA
nephropathy
Fish oil 6.0 g/d Corn oil
6.0 g/d
6 3
Higashihara
et al. (15)
2008 Japan 41 47.1 70.7 ADPKD EPA 2.4 g/d Untreated 24 3
Mori et al. (16) 2009 Australia 74 56.5 73.0 CKD Omega-3 capsules 4 g/d Olive oil
4.0 g/d
2 4
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patients had IgA nephropathy, if the duration of the follow-
up period was 424 months, or if the study was of high
quality. However, there were no significant differences
identified, based on predefined factors, between the effect
of omega-3 fatty acid supplementation and control of the
CCR and eGFR. Furthermore, subgroup analyses showed
heterogeneity between subgroups for the CCR based on the
follow-up duration.
Review of the funnel plots could not rule out potential
publication bias for proteinuria or the CCR. In addition, the
Egger and Begg tests revealed no evidence of publication
bias in any case for proteinuria, the CCR, or the eGFR.
’ DISCUSSION
This study was based on RCTs and explored all possible
correlations between omega-3 fatty acid supplementation
and proteinuria, the CCR, the eGFR, and the occurrence
ESRD. This quantitative study comprised 444 individuals
from 9 RCTs (8-16), with a broad range of patient charac-
teristics. The findings from this meta-analysis suggest that
omega-3 fatty acid supplementation is associated with a
lower risk of proteinuria but has no significant effect on the
CCR or eGFR, although it does significantly reduce the risk
of ESRD. Finally, subgroup analyses indicated that omega-3
fatty acids have a significant effect on lowering the risk of
proteinuria in several subpopulations.
A previous meta-analysis (27) suggested that there are
insufficient data to confirm the efficacy of omega-3 fatty acid
treatments for proteinuria and reduced renal function in IgA
nephropathy. However, another meta-analysis (28) suggested
that while omega-3 fatty acids have no benefit in terms of
preserving renal function, they can ameliorate proteinuria in
IgA nephropathy. In addition, the effects of omega-3 fatty
Figure 2 - Forest plot of the association of omega-3 fatty acid supplementation with proteinuria.
Figure 3 - Forest plot of the association of omega-3 fatty acid supplementation with the creatinine clearance rate (CCR).
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acids on proteinuria were not found to be dose dependent,
which was inconsistent with a previous study. The inherent
limitation of the previous studies is that few included or
acquired broad CIs (i.e., there was no statistically significant
difference); therefore, an updated meta-analysis of RCTs was
conducted to evaluate the efficacy of omega-3 fatty acids in
the treatment of chronic kidney disease.
Most of the findings in the present study were in agree-
ment with a large RCT recently published by Donadio et al.
(8). This trial comprised 106 patients with IgA nephropathy
who consumed 1.9 g/d EPA plus 1.4 g/d DHA and reported
longer renal progression for high-risk patients with IgA
nephropathy. The current study also indicated that omega-3
fatty acids significantly reduce the risk of ESRD and are
associated with a lower risk of proteinuria; this may be
because omega-3 fatty acids might be involved in blood
pressure control, as hypertension is a strong risk factor for
the progression of renal disease in patients with chronic
nephropathy. In addition, the stage of the disease at the time
of entry to the study might play an important role in its
progression. Furthermore, there were no significant differ-
ences in the CCR or eGFR between omega-3 fatty acid-
supplemented groups and control groups in this study,
whereas omega-3 fatty acid supplementation was associated
with a lower risk of ESRD. The reason for this finding could
be that several studies reported CCR and eGFR data,
whereas ESRD findings were not available, resulting in
variable outcomes.
Subgroup analyses suggested that omega-3 fatty acids
have a significant effect on the risk of proteinuria in several
subpopulations. However, these conclusions might be unreli-
able because smaller trials were included in the subsets.
Figure 4 - Forest plot of the association of omega-3 fatty acid supplementation with the estimated glomerular filtration rate (eGFR).
Figure 5 - Forest plot of the association of omega-3 fatty acid supplementation with the occurrence of end-stage renal disease (ESRD).
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Hence, a relative result is given, and a synthetic and compre-
hensive review is provided.
Three strengths of this study should be highlighted. First,
only RCTs, which should have no bias compared with
observational studies, were included. Second, the large
sample size allowed for quantitative assessment of the
association between omega-3 fatty acids and the risk of
decreased renal function and proteinuria; thus, the findings
are potentially more robust than those of any individual
study. Third, the subgroup analyses allowed the effect of
Table 2 - Subgroup analyses of the standard mean differences (SMDs) for proteinuria and the creatinine clearance rate (CCR) following
any or high-dose omega-3 fatty acid supplementation compared with no or low-dose omega-3 fatty acid supplementation,
respectively.
Outcomes Subgroup SMD and
95% CI
p value Heterogeneity
(%)
p value for
heterogeneity
p value for
heterogeneity
between
subgroups
Proteinuria Country
USA or Australia -0.36 (-0.64 to -0.09) 0.008 0.0 0.439 0.395
Europe -0.38 (-0.80 to 0.04) 0.077 0.0 0.448
Asia 0.09 (-0.53 to 0.70) 0.784 - -
Mean age (years)
40 or more -0.21 (-0.48 to 0.07) 0.144 0.0 0.551 0.233
o40 -0.47 (-0.80 to -0.14) 0.006 0.0 0.402
Percentage male
60 or more -0.33 (-0.57 to -0.09) 0.007 8.8 0.362 0.520
o60 -0.11 (-0.76 to 0.54) 0.736 0.0 0.624
Current disease status
IgA nephropathy -0.43 (-0.70 to -0.17) 0.001 0.0 0.617 0.118
Other -0.07 (-0.44 to 0.29) 0.693 0.0 0.538
Duration of the follow-up period (months)
24 or more -0.33 (-0.62 to -0.04) 0.026 6.1 0.372 0.749
o24 -0.27 (-0.61 to 0.07) 0.120 0.0 0.412
Study quality (Jadad score)
4 or 5 -0.36 (-0.64 to -0.09) 0.008 0.0 0.439 0.548
o4 -0.23 (-0.58 to 0.12) 0.197 3.4 0.376
CCR Country
USA or Australia 0.07 (-0.39 to 0.53) 0.767 31.9 0.230 0.164
Europe -0.34 (-1.76 to 1.07) 0.633 85.9 0.008
Asia 1.44 (-1.59 to 4.47) 0.352 94.0 o0.001
Mean age (years)
40 or more -0.06 (-0.57 to 0.44) 0.806 63.6 0.027 0.141
o40 1.40 (-1.70 to 4.51) 0.375 94.2 o0.001
Percentage male
60 or more -0.06 (-0.57 to 0.44) 0.806 63.6 0.027 0.141
o60 1.40 (-1.70 to 4.51) 0.375 94.2 o0.001
Current disease status
IgA nephropathy 0.44 (-0.80 to 1.67) 0.488 89.1 o0.001 0.918
Other 0.09 (-0.34 to 0.52) 0.680 26.6 0.256
Duration of the follow-up period (months)
24 or more -0.37 (-0.97 to 0.23) 0.224 56.5 0.100 0.005
o24 0.76 (-0.19 to 1.72) 0.116 83.3 o0.001
Study quality (Jadad score)
4 or 5 0.07 (-0.39 to 0.53) 0.767 31.9 0.230 0.962
o4 0.45 (-0.76 to 1.67) 0.464 89.0 o0.001
eGFR Country
USA or Australia 0.11 (-0.17 to 0.39) 0.451 7.4 0.356 0.708
Europe 0.22 (-0.43 to 0.86) 0.510 57.2 0.097
Mean age (years)
40 or more 0.20 (-0.23 to 0.64) 0.363 48.7 0.099 0.631
o40 0.08 (-0.25 to 0.40) 0.648 0.0 0.871
Percentage male
60 or more 0.17 (-0.15 to 0.49) 0.304 37.0 0.160 0.735
o60 0.03 (-0.62 to 0.68) 0.927 - -
Current disease status
IgA nephropathy 0.13 (-0.17 to 0.43) 0.391 18.7 0.296 0.869
Other 0.19 (-0.63 to 1.01) 0.646 67.8 0.078
Duration of the follow-up period (months)
24 or more 0.11 (-0.19 to 0.41) 0.460 0.0 0.851 0.831
o24 0.18 (-0.37 to 0.73) 0.515 61.0 0.053
Study quality (Jadad score)
4 or 5 0.11 (-0.17 to 0.39) 0.451 7.4 0.356 0.708
o4 0.22 (-0.43 to 0.86) 0.510 57.2 0.097
63
CLINICS 2017;72(1):58-64 Omega-3 fatty acids and chronic kidney disease
Hu J et al.
omega-3 fatty acids to be evaluated in specific subpopu-
lations.
The limitations of this study were as follows: (1) in a
meta-analysis of published studies, publication bias is an
inevitable problem; (2) subgroup analyses and publication
bias analyses were not performed for ESRD because of a
smaller number of relevant trials, resulting in less available
data; and (3) the analysis used pooled data (individual data
were not available), which restricted us from performing a
more detailed analysis and obtaining more comprehensive
results.
The results of this study suggest that omega-3 fatty acids
significantly reduce the risk of ESRD and are associated with
a lower risk of proteinuria. Future trials should focus on the
specific disease status to analyze the efficacy of omega-3 fatty
acids in the treatment of chronic nephropathy of differing
severities.
’ AUTHOR CONTRIBUTIONS
Hu J, Liu Z and Zhang H contributed to the study conception and design
and the data acquisition, analysis and interpretation. Hu J and Zhang H
were involved in drafting the manuscript and in critically revising it for
important intellectual content. All of the authors approved the ﬁnal version
of the manuscript to be published.
’ REFERENCES
1. Noel LH, Droz D, Gascon M, Berger J. Primary IgA nephropathy: from the
first-described cases to the present. Semin Nephrol. 1987;7(4):351-4.
2. Scholl U, Wastl U, Risler T, Braun N, Grabensee B, Heering P, et al. The
"point of no return" and the rate of progression in the natural history of
IgA nephritis. Clin Nephrol. 1999;52(5):285-92.
3. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association
between omega-3 fatty acid supplementation and risk of major cardio-
vascular disease events: a systematic review and meta-analysis. JAMA.
2012;308(10):1024-33, http://dx.doi.org/10.1001/2012.jama.11374.
4. Djousse L, Akinkuolie AO, Wu JH, Ding EL, Gaziano JM. Fish con-
sumption, omega-3 fatty acids and risk of heart failure: a meta-analysis.
Clin Nutr. 2012;31(6):846-53, http://dx.doi.org/10.1016/j.clnu.2012.05.010.
5. Hogg RJ. A randomized, placebo-controlled, multicenter trial evaluating
alternate-day prednisone and fish oil supplements in young patients with
immunoglobulin A nephropathy. Scientific Planning Committee of the
IgA Nephropathy Study. Am J Kidney Dis. 1995;26(5):792-6, http://dx.
doi.org/10.1016/0272-6386(95)90445-X.
6. De Caterina R, Caprioli R, Giannessi D, Sicari R, Galli C, Lazzerini G, et al.
n-3 fatty acids reduce proteinuria in patients with chronic glomerular
disease. Kidney Int. 1993;44(4):843-50, http://dx.doi.org/10.1038/ki.
1993.320.
7. Cheng IK, Chan PC, Chan MK. The effect of fish-oil dietary supplement
on the progression of mesangial IgA glomerulonephritis. Nephrol Dial
Transplant. 1990;5(4):241-6, http://dx.doi.org/10.1093/ndt/5.4.241.
8. Donadio JV Jr., Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC.
The long-term outcome of patients with IgA nephropathy treated with
fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am
Soc Nephrol. 1999;10(8):1772-7.
9. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Com-
bined treatment with renin-angiotensin system blockers and poly-
unsaturated fatty acids in proteinuric IgA nephropathy: a randomized
controlled trial. Nephrol Dial Transplant. 2009;24(1):156-60, http://dx.
doi.org/10.1093/ndt/gfn454.
10. Uchiyama-Tanaka Y, Mori Y. Effects of eicosapentaenoic acid supple-
mentation on immunoglobulin A nephropathy. Ther Apher Dial. 2010;
14(3):303-7, http://dx.doi.org/10.1111/j.1744-9987.2009.00791.x.
11. Alexopoulos E, Stangou M, Pantzaki A, Kirmizis D, Memmos D. Treat-
ment of severe IgA nephropathy with omega-3 fatty acids: the effect of a
"very low dose" regimen. Ren Fail. 2004;26(4):453-9, http://dx.doi.org/
10.1081/JDI-200026763.
12. Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of
high-dose compared with low-dose omega-3 fatty acids in severe IgA
nephropathy. J Am Soc Nephrol. 2001;12(4):791-9.
13. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy
with eicosapentanoic acid (EPA): a two-year prospective trial. Clin
Nephrol. 1989;31(3):128-31.
14. Pettersson EE, Rekola S, Berglund L, Sundqvist KG, Angelin B, Diczfalusy
U, et al. Treatment of IgA nephropathy with omega-3-polyunsaturated
fatty acids: a prospective, double-blind, randomized study. Clin Nephrol.
1994;41(4):183-90.
15. Higashihara E, Nutahara K, Horie S, Muto S, Hosoya T, Hanaoka K, et al.
The effect of eicosapentaenoic acid on renal function and volume
in patients with ADPKD. Nephrol Dial Transplant. 2008;23(9):2847-52,
http://dx.doi.org/10.1093/ndt/gfn144.
16. Mori TA, Burke V, Puddey I, Irish A, Cowpland CA, Beilin L, et al. The
effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure
and heart rate in chronic kidney disease: a randomized controlled trial.
J Hypertens. 2009;27(9):1863-72, http://dx.doi.org/10.1097/HJH.0b0
13e32832e1bd9.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. PLoS Med. 2009;6(7):e1000097, http://dx.doi.org/10.1371/jour-
nal.pmed.1000097.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ,
et al. Assessing the quality of reports of randomized clinical trials: is
blinding necessary? Control Clin Trials. 1996;17(1):1-12, http://dx.doi.
org/10.1016/0197-2456(95)00134-4.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin
Trials. 1986;7(3):177-88, http://dx.doi.org/10.1016/0197-2456(86)90046-2.
20. Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-
analysis in decision models. Med Decis Making. 2005;25(6):646-54,
http://dx.doi.org/10.1177/0272989X05282643.
21. Deeks JJ, Higgins J, Altman DG. Analysing Data and Undertaking
Meta-Analyses. Cochrane Handbook for Systematic Reviews of Inter-
ventions: Cochrane Book Series. 2008:243-96.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency
in meta-analyses. BMJ. 2003;327(7414):557-60, http://dx.doi.org/10.1136/
bmj.327.7414.557.
23. Tobias A. Assessing the influence of a single study in the meta-analysis
estimate. Stata Tech Bull. 1999;47:15-17.
24. Deeks J. J, Altman D. G, Bradburn M. J. Statistical methods for examining
heterogeneity and combining results from several studies in meta-analy-
sis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in
Health Care: Metaanalysis in Context. 2nd ed. London: BMJ Books, 2001:
285-312.
25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315(7109):629-34, http://
dx.doi.org/10.1136/bmj.315.7109.629.
26. Begg CB, Mazumdar M. Operating characteristics of a rank correlation
test for publication bias. Biometrics. 1994;50(4):1088-101, http://dx.doi.
org/10.2307/2533446.
27. Chou HH, Chiou YY, Hung PH, Chiang PC, Wang ST. Omega-3 fatty
acids ameliorate proteinuria but not renal function in IgA nephropathy:
a meta-analysis of randomized controlled trials. Nephron Clin Pract.
2012;121(1-2):c30-5, http://dx.doi.org/10.1159/000341929.
28. Liu LL, Wang LN. Omega-3 fatty acids therapy for IgA nephropathy:
a meta-analysis of randomized controlled trials. Clin Nephrol. 2012;
77( 2):119-25, http://dx.doi.org/10.5414/CN107244.
64
Omega-3 fatty acids and chronic kidney disease
Hu J et al.
CLINICS 2017;72(1):58-64
